Mode
Text Size
Log in / Sign up
N/A N=36 Randomized Other

Daytime vs. Delayed Eating Among Obese Individuals

Obesity

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Nov 2025
Primary outcome: Primary: Body Mass (Weight) — -2.1067; -2.1887 kg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Eating Condition (Behavioral); No Intervention; withdrawn before randomization (Other)
Age
Adult · 21+ yrs
Sex
All
Sponsor
University of Pennsylvania
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Body Mass (Weight)
-2.1067; -2.1887
PRIMARY
Adiposity - Total Body Fat
-0.3300; -0.4833
PRIMARY
Energy Homeostasis Outcomes - REE
-32.4723; 47.0390
PRIMARY
Energy Homeostasis - Respiratory Quotient
-0.203; -0.0197

Summary

The randomized, cross-over design study is designed to determine how timing of eating affects weight, adiposity, energy metabolism, and gene expression. Obese participants will be provided isocaloric meals and snacks to be consumed in one of two prescribed eating conditions -- daytime eating and delayed eating.

Eligibility Criteria

Inclusion Criteria

  • age 21-50
  • BMI of 30-50 kg/m2
  • stable weight (±10 lb) over the previous 6 months
  • women must be pre-menopausal with regular menstrual cycles

Exclusion Criteria

  • unstable, serious medical conditions
  • use of medicine linked to weight gain/loss
  • cardiac conditions
  • cancer
  • diabetes
  • autoimmune disease
  • use of illicit drugs, melatonin, diuretics or hypnotics
  • involved in a current weight loss program
  • presence of an untreated sleep disorder (determined by surveys and actigraphy)
  • those who work shift work
  • those with extreme chronotypes
  • habitual waking outside of 0600h-0930h
  • habitual bedtime 2400h
  • sleep duration of 8.5 h/night.
  • psychiatric exclusions will be: depression (Patient Health Questionnaire-9 score ≥9), lifetime bipolar disorder, psychosis, or eating disorder; or any other severe psychiatric disorder judged to interfere with study adherence as assessed by the MINI International Neuropsychiatric Interview.
  • structured exercise >3 d/wk, for >30 min measured by exercise logs and actigraphy; normal activity levels are required during the study (±30 min/wk of baseline level).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03354169). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search